Tirzepatide

Plain-language summary

A dual GIP and GLP-1 receptor agonist given by weekly injection, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management and obstructive sleep apnea with obesity (Zepbound).

Regulatory status

Evidence snapshot

Established. Supported by multiple well-conducted randomized trials and/or systematic reviews with consistent results.

How it works

Activates both the GIP and GLP-1 incretin receptors, improving insulin secretion, lowering glucagon, slowing gastric emptying, and reducing appetite.

Approved uses and researched uses

Researched uses are studied but not FDA-approved and may be off-label. This is not a recommendation to use them.

Known risks and uncertainties

Common effects are nausea, diarrhea, vomiting, constipation, and decreased appetite. Serious potential risks include pancreatitis, gallbladder disease, and hypoglycemia when combined with insulin or sulfonylureas. The label carries a boxed warning for thyroid C-cell tumors from rodent studies.

Cautions and contraindications

Contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and in those with serious hypersensitivity to tirzepatide.

Consumer considerations

• Mounjaro and Zepbound are the same molecule approved for different indications.
• May reduce the absorption of oral medications, including oral contraceptives, because it slows digestion.
• Weight tends to return after stopping without sustained lifestyle change.
• Doses are titrated up over weeks to reduce GI effects.
• Compounded tirzepatide is not FDA-approved.

Questions to ask a licensed clinician

• Which indication am I being treated for and at what target dose?
• How does this interact with my other medications, including oral contraceptives?
• What GI side effects should I expect and how do I manage them?
• Do I have any thyroid or pancreatic history that raises my risk?
• What is the plan if I need to stop the medication?

Sources